RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Vonetize Plc: Possible acquisition of Takoomi will provide foothold in the smart video advertising space; price target unchanged

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading